The role of cabergoline medicine in treating cushing s syndrome: a systematic review

Introduction Cushing s syndrome is an endocrine disorder caused by the excessive production of corticosteroid hormones and adrenocortical hyperplasia. cushing s disease is treated by tumor surgery and drug therapy to control the secretion of the hormone. this review study was conducted to investigate the role of cabergoline in the treatment of cushing s syndrome. Methods This article is a systematic review using the keywords: mesh cushing syndrome, cabergoline, cortisol, adrenocorticotropic hormone atpubmed, medline, and google scholar databases, using the english equivalents of this vocabulary in the google scholar and sid sites until 2017 year. after initial research by two independent individuals from among 932 articles, 96 articles related to the subject were included in the full text and abstract. data reporting was done qualitatively. Results Cabergolin is a d1 and d2 receptor dopamine agonist that reduces the prolactin secretion by stimulating the brain. studies have shown that cabergoline is effective in controlling cortisol secretion for 1-2 years in one-third of the population of infected patients. in fact, this drug may be effective in treating cushing s syndrome by reducing the amount of cortisol. Conclusion Cabergolin can treat prolactinoma by decreasing prolactin levels and reducing the tumor. combining ketoconazole with cabergoline is a hopeful way of treating it. future studies are inversely related to the increase of morbidity for cushing s disease and the diagnosis of the pathogenesis of tumors based on this obscure syndrome to identify drug therapies. judging about the definitive effectiveness of these interventions requires more extensive research with higher sample sizes.